ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2026
Prevalence of Large Academic Research Institutions and NCI Designated Cancer Centers with Corynebacterium bovis Infections among Immunodeficient Mice in the United States from 2015 to 2023.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corynebacterium bovis is an opportunistic bacterium that infects the skin of immunodeficient mice used in biomedical research. C. bovis was first deemed clinically significant in the mid-1990s. To date, only limited data are available on the prevalence of this infection among research institutions in the United States. Here we define prevalence as the proportion of institutions that have C. bovis-infected mice in their care. To determine the national prevalence of C. bovis infections, we performed a survey of animal resource program directors and veterinarians at the NIH top 50 funded academic institutions and all Designated Cancer Centers of the National Cancer Institute. This survey was initially performed in 2015 and then expanded and repeated in 2023. Survey questions assessed institutional C. bovis status (positive, negative, or unsure), surveillance practices, and attempts to establish C. bovis-free colonies through bioexclusion. Responses were obtained from 81 institutions in 2015 and 85 in 2023, achieving 100% participation in both years. Between 2015 and 2023, C. bovis-positive status declined slightly (49% to 45%), negative responses dropped more sharply (38% to 22%), and uncertainty increased (12% to 33%), resulting in an overall shift in response distribution (P = 0.002). Despite the increased uncertainty, 69% (59/85) of all institutions in 2023 performed active surveillance for C. bovis in some form. Similarly, of institutions that self-report as having C. bovis-infected mice, 84.2% (32/38) performed C. bovis surveillance, and 78.9% (30/38) have used bioexclusion techniques. Overall, 71.7% (61/85) of institutions recognize C. bovis as an actionable pathogen. Conversely, between 20% and 28% (17 and 24/85) of institutions in 2023 did not see C. bovis as an actionable pathogen and, if present, chose to tolerate it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.